File
J. Yamanoi1, T. Miyazaki1, Y. Hatanaka2
1Osu Hospital, Nagoya, Japan, 2Suzuka University of Medical Science, Suzuka, Japan
Background: Performing Electrical Stimulation (ES) in the acute phase of stroke prevents muscle atrophy and prevents sarcopenia complications.
However, the effect of ES on preventing muscular atrophy with or without Prestroke sarcopenia is unknown.
However, the effect of ES on preventing muscular atrophy with or without Prestroke sarcopenia is unknown.
Purpose: The purpose of this study was to investigate the effects of sarcopenia before stroke onset on ES.
Methods: Subjects in this study were randomized by SARC-F score (non-sarcopenic: SARC-F score <4, and pre-stroke sarcopenic: SARC-F score ≥4).
Patients with non-sarcopenia and pre-stroke sarcopenia were divided into es group (non-sarcopenia + es (n = 23) and pre-stroke sarcopenia + es group (n = 24)) and non-es group (non-sarcopenia + non-es (n = 26) and pre-stroke sarcopenia + non-es group (n = 25)).
The primary outcome was the muscle thickness (MT) of the affected and unaffected quadriceps femoris muscles using B-mode lateral ultrasound imaging. MT was measured on admission and after intervention.
The ES group underwent NMES (5 days/week for 2 weeks, symmetric biphasic current 100 Hz, pulse width 1 msec, 30 min/day, duty cycle 10 sec on/20 sec off, intensity: 20-40 mA).
Statistical analysis assessed differences between the four groups using two-way repeated measures ANOVA (p<0.05).
Patients with non-sarcopenia and pre-stroke sarcopenia were divided into es group (non-sarcopenia + es (n = 23) and pre-stroke sarcopenia + es group (n = 24)) and non-es group (non-sarcopenia + non-es (n = 26) and pre-stroke sarcopenia + non-es group (n = 25)).
The primary outcome was the muscle thickness (MT) of the affected and unaffected quadriceps femoris muscles using B-mode lateral ultrasound imaging. MT was measured on admission and after intervention.
The ES group underwent NMES (5 days/week for 2 weeks, symmetric biphasic current 100 Hz, pulse width 1 msec, 30 min/day, duty cycle 10 sec on/20 sec off, intensity: 20-40 mA).
Statistical analysis assessed differences between the four groups using two-way repeated measures ANOVA (p<0.05).
Results: In the pre-stroke sarcopenia and non-sarcopenia + non-Es groups, the reduction in muscle atrophy progressed after 2 weeks (p<0.05). On the other hand, the pre-stroke sarcopenia and non-sarcopenia+Es groups reduced the rate of muscle atrophy by 5%(p > 0.05).
Pre-stroke sarcopenia and non-sarcopenia + Es groups were better in affected and non-affected side outcomes than pre-stroke sarcopenia and non-sarcopenia + non-Es groups at 2 weeks Achieved low MT (p < 0.001).
Pre-stroke sarcopenia and non-sarcopenia + Es groups were better in affected and non-affected side outcomes than pre-stroke sarcopenia and non-sarcopenia + non-Es groups at 2 weeks Achieved low MT (p < 0.001).
Conclusions: It was suggested that the effect of es to prevent muscle atrophy in the acute phase of stroke prevents muscle atrophy regardless of the presence or absence of pre-stroke sarcopenia.
In particular, the administration of es for pre-stroke sarcopenic patients prevents muscle atrophy.
In particular, the administration of es for pre-stroke sarcopenic patients prevents muscle atrophy.
Implications: The Es group suppressed muscle atrophy significantly more than the non-Es group. In particular, es is effective in preventing muscle atrophy in patients with pre-stroke sarcopenia.
Funding acknowledgements: The authors declare no conflicts of interest related to this manuscript.
Keywords:
Sarcopenia
Neuromuscular Electrical Stimulation
Acute stroke
Sarcopenia
Neuromuscular Electrical Stimulation
Acute stroke
Topics:
Older people
Musculoskeletal: lower limb
Neurology: stroke
Older people
Musculoskeletal: lower limb
Neurology: stroke
Did this work require ethics approval? Yes
Institution: Aichi Saiseikai Hospital
Committee: Aichi Saiseikai Hospital
Ethics number: 201908
All authors, affiliations and abstracts have been published as submitted.
